Neuromyelitis optica (NMO): antibodies

Evidence-based neurology checklist on neuromyelitis optica (nmo): antibodies: Aquaporin 4 antibody (AQP4-Ab): manifestations Aquaporin 4 antibodies are present in 70% of cases They may be more prevalent in Blacks Assessment with cell-based assay (CBA) is better than with tissue or ELISA CSF levels…

Aquaporin 4 antibody (AQP4-Ab): manifestations

  • Aquaporin 4 antibodies are present in 70% of cases
  • They may be more prevalent in Blacks
  • Assessment with cell-based assay (CBA) is better than with tissue or ELISA
  • CSF levels are less sensitive than serum values
  • Seroconversion to negative over time occurs in 11% of cases

Aquaporin 4 antibody (AQP4-Ab): causes of false negative tests

Aquaporin 4 antibody (AQP4-Ab): causes of false positive tests

Anti MOG antibody: features

Anti MOG antibody: presentations other than classical NMO

Anti Argonaute antibody

Other antibodies

References

  1. Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008; 128:209-217.
  2. Palace J, Leite I, Jacob A. A practical guide to the treatment of neuromyelitis optica. Pract Neurol 2012; 12:209-214.
  3. Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical exaltation and treatment of transverse myelitis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 77:2128-2134.
  4. Sherman E, Han MH. Acute and chronic management of neuromyelitis optica spectrum disorder. Curr Treat Options Neurol 2015; 17:48. 
  5. Sand IK. Neuromyelitis optica spectrum disorders. Continuum (Minneap Minn) 2016; 22:864-896. 
  6. And 9 more. Subscribe to see the full list

Related checklists

Loading...